Canertinib 2HCl is primarily used in cancer research and treatment, specifically targeting certain types of cancers by inhibiting specific enzymes involved in tumor growth. It is often studied for its potential in treating cancers such as breast cancer, lung cancer, and glioblastoma, where it helps to block the activity of epidermal growth factor receptors (EGFRs) that promote cancer cell proliferation. Researchers utilize this compound to explore its efficacy in combination therapies, aiming to enhance the effectiveness of existing cancer treatments. Additionally, it serves as a valuable tool in preclinical studies to better understand the mechanisms of EGFR signaling pathways and their role in cancer progression.